SeaSpine to Participate in the Canaccord Musculoskeletal Conference

Rhea-AI Summary

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced its participation in the Canaccord Musculoskeletal Conference on March 22, 2022, at 2:30 pm ET. A live and archived webcast will be accessible through the SeaSpine website.

SeaSpine specializes in surgical solutions for spinal disorders, providing a portfolio of orthobiologics and spinal implants, as well as surgical navigation systems for neurosurgeons and orthopedic spine surgeons.

News Market Reaction – SPNE

+1.35%

+1.35% Session move

In the trading session that priced this news, SPNE gained 1.35%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company will participate in the Canaccord Musculoskeletal Conference on Tuesday, March 22, 2022 beginning at 2:30 pm ET.

A live and archived webcast of the event will be available from the Investors section of the SeaSpine website at: www.seaspine.com.

About SeaSpine

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants and software product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact
Leigh Salvo
ir@seaspine.com

FAQ

When is SeaSpine participating in the Canaccord Musculoskeletal Conference?

SeaSpine will participate in the Canaccord Musculoskeletal Conference on March 22, 2022, at 2:30 pm ET.

How can I watch the SeaSpine conference webcast?

You can watch the live and archived webcast of the SeaSpine conference on their website at www.seaspine.com.

What is the main focus of SeaSpine's business?

SeaSpine focuses on designing and developing surgical solutions for spinal disorders, including orthobiologics and spinal implants.

What products does SeaSpine offer for spinal surgeries?

SeaSpine offers a comprehensive portfolio of orthobiologics, spinal implants, and a surgical navigation system for various spinal procedures.